SRPT vs. VTRS, LEGN, APLS, UTHR, RXDX, RDY, KRTX, JAZZ, TEVA, and ROIV
Should you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include Viatris (VTRS), Legend Biotech (LEGN), Apellis Pharmaceuticals (APLS), United Therapeutics (UTHR), Prometheus Biosciences (RXDX), Dr. Reddy's Laboratories (RDY), Karuna Therapeutics (KRTX), Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical preparations" industry.
Sarepta Therapeutics vs.
Viatris (NASDAQ:VTRS) and Sarepta Therapeutics (NASDAQ:SRPT) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability, risk and community ranking.
Viatris currently has a consensus price target of $12.67, indicating a potential upside of 35.04%. Sarepta Therapeutics has a consensus price target of $168.76, indicating a potential upside of 32.19%. Given Viatris' higher possible upside, equities analysts plainly believe Viatris is more favorable than Sarepta Therapeutics.
Viatris has a net margin of 12.05% compared to Sarepta Therapeutics' net margin of -114.30%. Viatris' return on equity of 19.19% beat Sarepta Therapeutics' return on equity.
74.7% of Viatris shares are held by institutional investors. Comparatively, 87.3% of Sarepta Therapeutics shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 7.4% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Viatris has higher revenue and earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sarepta Therapeutics had 5 more articles in the media than Viatris. MarketBeat recorded 10 mentions for Sarepta Therapeutics and 5 mentions for Viatris. Viatris' average media sentiment score of 0.84 beat Sarepta Therapeutics' score of 0.52 indicating that Viatris is being referred to more favorably in the media.
Viatris has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
Sarepta Therapeutics received 1371 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 75.49% of users gave Sarepta Therapeutics an outperform vote while only 41.18% of users gave Viatris an outperform vote.
Summary
Viatris beats Sarepta Therapeutics on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sarepta Therapeutics Competitors List
Related Companies and Tools
